Atrophic Gastritis and<i>Helicobacter pylori</i>Infection in Patients with Reflux Esophagitis Treated with Omeprazole or Fundoplication

Kuipers, Ernst J.; Lundell, Lars; Klinkenberg‐Knol, Elly C.; Havu, Niilo; Festen, H. P. M.; Liedman, Bengt; Lamers, C. B. H. W.; Jansen, J. B. M. J.; Dalenbäck, Jan; Snel, P.; Nelis, G. F.; Meuwissen, S. G. M.

doi:10.1056/nejm199604183341603

Cited by 708 publications

(492 citation statements)

References 23 publications

Supporting

Mentioning

447

Contrasting

Unclassified

Order By: Relevance

“…High incidence rates of CAG were furthermore, observed in cohorts of H. pylori positive patients treated with omeprazole for reflux esophagitis [14,20,22]. This finding might be explained by the joint impact of long-term H. pylori infection and omeprazole therapy on lowering of the gastric acidity which makes the gastric mucosa more prone to atrophy.…”

Section: Discussionmentioning

confidence: 92%

“…Another 4 articles were excluded for the following reasons: all patients had either chronic gastritis or CAG at baseline, incidence of CAG was based on biopsies and not on study participants, incidence of CAG and metaplasia or either of them were grouped together and in one study, no mean follow-up time could be estimated. Due to these exclusions, only 14 studies (from 15 articles) with information on the incidence of CAG could be included in this review [10][11][12][13][14][15][16][17][18][19][20][21][22][23][24]. According to the above described criteria, all of these studies included more than 15 study participants who were diagnosed to be free of CAG at baseline, either by histology ('normal' or 'superficial gastritis') or by serum pepsinogen (PG) levels.…”

Section: Resultsmentioning

confidence: 99%

“…2 of the studies were conducted in multiple centres in different countries [20,22]. Studies were carried out in Sweden, [10] Columbia, [11] the Netherlands, [12,13] the Netherlands and Sweden, [14] Finland, [15] Estonia, [16,24] Japan, [17,23] USA, [18] Slovenia, [19] Australia, Canada, Germany, and the Netherlands, [20] Germany [21] and Denmark, Finland, Norway and Sweden [22]. Most of the studies were not population-based and consisted of symptomatic patients.…”

Section: Resultsmentioning

confidence: 99%

“…The lowest incidence (0%) was observed in two study populations, one made up of a very special cohort of 71 patients with reflux esophagitis, who were treated by fundoplication (an endoscopic procedure of wrapping the fundus around the esophagus for treatment of reflux esophagitis) and followed for a mean period of 5 years [14]. The other study population consisted of 45 patients who had undergone successful H. pylori eradication therapy before the start of the study [19].…”

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Incidence of chronic atrophic gastritis: systematic review and meta-analysis of follow-up studies

et al. 2010

View full text Add to dashboard Cite

Chronic atrophic gastritis (CAG) is an important precursor lesion of intestinal gastric cancer. As it is typically asymptomatic, epidemiological data on the incidence of CAG are sparse. We aimed to provide an overview of published data on CAG incidence (overall and according to risk factors) from follow-up studies. Articles with information on incidence of CAG published in English until 26th of July 2009 were identified through a systematic MEDLINE and EMBASE search. Data extracted include study characteristics and key findings regarding the incidence of CAG. A meta-analysis was performed on the association between Helicobacter pylori infection and CAG incidence. Overall, data on CAG incidence were available from 14 studies, in 7 studies incidence could be estimated according to H. pylori infection. Most studies were conducted in symptomatic or high risk populations and the maximum number of incident cases was 284. Incidence estimates ranged from 0 to 11% per year and were consistently below 1% in patients not infected with H. pylori. The highest incidence was observed in a special study conducted on ulcer patients treated by proximal gastric vagotomy. Rate ratios for the association between H. pylori infection and CAG incidence ranged from 2.4 to 7.6 with a summary estimate of 5.0 (95% confidence interval: 3.1-8.3). Incidence of CAG is very low in the absence of H. pylori infection. There is a need for more population-based studies to provide comparable estimates of incidence and the impact of risk factors in the development of CAG.

show abstract

Section: Discussionmentioning

confidence: 92%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Incidence of chronic atrophic gastritis: systematic review and meta-analysis of follow-up studies

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Ainsi, les IPP augmenteraient la concentration en nitrates, connus pour être des carcinogènes gastriques, dans le suc gastrique [32]. L'hypochlorhydrie est par ailleurs un facteur favorisant le développement d'Helicobacter pylori, bactérie impliquée dans les phénomènes de carcinogénèse gastrique [33].…”

Section: Cancers Digestifsunclassified

Effets indésirables des inhibiteurs de la pompe à proton : faut-il craindre de les prescrire au long cours ?

Roulet

Vernaz

Giostra

et al. 2012

La Revue de Médecine Interne

View full text Add to dashboard Cite

Mots clés :Inhibiteurs de la pompe à proton Fractures ostéoporotiques Infections Cancer gastrique Pharmacodépendance r é s u m é La prévalence des traitements de longue durée par inhibiteurs de la pompe à proton (IPP) est en augmentation. Si leur tolérance à court terme est bonne, des réserves ont vu le jour sur d'éventuels effets indésirables graves associés à une exposition prolongée. Ainsi, l'association avec le risque fracturaire semble être confirmée, notamment au niveau vertébral, ainsi que le risque d'effet rebond sur la sécrétion acide à l'arrêt du traitement. Le risque de pneumopathie communautaire n'est pas établi dans la population générale et semble limité aux patients les plus fragiles. L'association avec le risque d'infection digestive à Clostridium difficile est probable. Les cas de néphrite tubulo-intestitielle sont rares mais peuvent conduire à une insuffisance rénale chronique. Les données disponibles sont encore insuffisantes pour évaluer le risque de carence en vitamine B12, en fer ou en magnésium et le risque de cancer digestif, même si des bases physiopathologiques existent dans le cas du cancer gastrique. Il existe des interactions avec de nombreux autres médicaments, notamment ceux qui sont métabolisés par certaines isoenzymes du cytochrome P450. Enfin, la balance bénéfice-risque de l'utilisation des IPP au long cours chez l'enfant semble défavorable dans la plupart des cas.© 2012 Société nationale française de médecine interne (SNFMI). Publié par Elsevier Masson SAS. Tous droits réservés. Keywords: Proton pump inhibitors Osteoporotic fractures Infection Stomach neoplasms Substance withdrawal syndrome a b s t r a c tLong-term treatment with proton pump inhibitors (PPI) is becoming more prevalent. Although they are well tolerated in the short term, serious concerns about long-term use have arisen. Recent data suggest that the latter is associated with an increased risk for osteoporotic fracture (especially vertebral), Clostridium difficile infection and rebound acid hypersecretion after treatment discontinuation. Acute interstitial nephritis is rare but may progress to chronic renal failure. An increased risk of communityacquired pneumonia has not been established in the general population and seems limited to the most vulnerable patients. Consistent data are still missing to correctly assess the risk of iron deficiency, vitamin B12 deficiency or hypomagnesaemia and the risk of digestive malignant diseases, despite the pathophysiological basis that exists concerning gastric malignancy. Many drug interactions can occur on long-term treatment, including some that imply the cytochrome P450 enzymes. Finally, the risk-benefit balance for a chronic PPI use in children seems unfavorable in most cases.

show abstract

Atrophic Body Gastritis in Patients With Autoimmune Thyroid Disease

Centanni¹,

Marignani²,

Gargano³

et al. 1999

Arch Intern Med

154

View full text Add to dashboard Cite

Atrophic Gastritis andHelicobacter pyloriInfection in Patients with Reflux Esophagitis Treated with Omeprazole or Fundoplication

Abstract: Patients with reflux esophagitis and H. pylori infection who are treated with omeprazole are at increased risk of atrophic gastritis.

Cited by 708 publications

References 23 publications

Incidence of chronic atrophic gastritis: systematic review and meta-analysis of follow-up studies

Incidence of chronic atrophic gastritis: systematic review and meta-analysis of follow-up studies

Effets indésirables des inhibiteurs de la pompe à proton : faut-il craindre de les prescrire au long cours ?

Atrophic Body Gastritis in Patients With Autoimmune Thyroid Disease

Contact Info

Product

Resources

About